MarginsXMarginsX
Home › Markets › Health Care › RLAY

Relay Therapeutics Inc. (RLAY)

RLAY trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$17.27
-4.53% on the day
Market cap
$3.8B
Mid cap
Revenue · 2025
$15.4M
+53.4% on 2024
Net income · 2025
-$276.5M
-1800.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/0001193125-26-076739-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRLAY on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001812364
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$15.4M
Net income-$276.5M
Operating income-$302.7M
Net margin-1800.6%
Operating margin-1971.6%
Revenue growth+53.4%
Cash$84.0M
Total assets$621.3M
P/E (computed)Net income was not positive
P/S (computed)248.5×

Warning signs

Cash runway
7.0 months
$124.2M cash at September 30, 2026
Share count, 1 year
+27.5%
2025-10-31 to 2026-10-30 · +79.3% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$129.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$124.2M cash; operating cash flow -$53.5M a quarter.Report 2026-09-30
Shares outstanding220,959,470 (2026-10-30); 173,322,385 a year earlier; 123,268,740 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-08-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $129.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$81.7M-$63.9M$124.2MNo debt tags$10.3M10-Q 2026-11-04
Q2 2026
2026-06-30
$350K-$83.7M-$54.1M$121.2MNo debt tags$10.3M10-Q 2026-08-06
Q1 2026
2026-03-31
$3.0M-$73.3M-$51.1M$204.6MNo debt tags$10.7M10-Q 2026-05-05
Q4 2025
2025-12-31
$7.0M-$54.9M-$44.9M$84.0MNo debt tags$15.4M10-K 2026-02-26
Q3 2025
2025-09-30
$0-$74.1M-$62.1M$91.6MNo debt tags$8.4M10-Q 2025-11-06
Q2 2025
2025-06-30
$677K-$70.4M-$55.3M$113.9MNo debt tags$8.4M10-Q 2026-08-06
Q1 2025
2025-03-31
$7.7M-$77.1M-$73.2M$93.5MNo debt tags$7.7M10-Q 2026-05-05
Q4 2024
2024-12-31
$0-$76.0M-$57.9M$124.3MNo debt tags$10.0M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-06
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 557 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.7%
1 month+4.2%
3 months-9.2%
Year to date+113.8%
1 year+180.5%
From 52-week high-12.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TARSTarsus Pharmaceuticals Inc.$78.68-1.99%$3.9B
CRSPCRISPR Therapeutics AG Common Shares$40.37-4.43%$3.9B
IOVAIovance Biotherapeutics Inc.$7.55-2.71%$3.5B
ADPTAdaptive Biotechnologies Corporation$27.87-4.03%$4.5B
ADMAADMA Biologics Inc$13.47-1.54%$3.0B
VCELVericel Corporation$57.48+0.91%$2.9B
DNLIDenali Therapeutics Inc.$18.08-3.52%$2.9B
SRRKScholar Rock Holding Corporation$44.54+3.09%$5.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier